ClinicalTrials.gg
CompletedNCT03082235Updated Sep 7, 2018

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

A Phase 1 interventional study of E6742 and Placebo in Healthy Participants, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-07.

Sponsored by Eisai Inc. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Oct 2017, 9 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Study E6742-A001-001 is a randomized, double-blind, placebo-controlled, single ascending dose study conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending oral doses of E6742 in healthy adult participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • Healthy participants
  • E6742
  • pharmacokinetics
03

In context

Lead sponsor

Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Nonsmoking, male or female, age ≥18 years and ≤45 years old at the time of
  • (BMI) ≥18 and \<32 kilograms per meters squared (kg/m2) at Screening

Exclusion criteria

Exclusion Criteria:

  • Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin [β-hCG] or human chorionic gonadotropin [hCG] test with a minimum sensitivity of 25 International Units per Liter [IU/L] or equivalent units of β-hCG [or hCG]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
  • Males who have not had a successful vasectomy (confirmed azoospermia) or they and their female partners do not meet the criteria above (ie, not of or practicing highly effective throughout the study period and for 5 times the half-life of the study drug plus 90 days after study drug discontinuation). No sperm donation is allowed during the study period and for 5 times the half-life of the study drug plus 90 days after study drug discontinuation.
  • Any history of gastrointestinal surgery that may affect pharmacokinetic (PK) profiles of E6742 (eg, hepatectomy, nephrectomy, digestive organ resection) at Screening
  • A prolonged interval (QTcF >450 ms) demonstrated on at Screening or Baseline
  • Persistent systolic blood pressure >130 mmHg or diastolic blood pressure >85 mmHg diastolic at Screening or Baseline Heart rate less than 50 or more than 100 beats/min at Screening or Baseline
  • Known history of prolonged QT/QTc interval
  • Left bundle branch block
  • Known history of myocardial infarction or active ischemic heart disease
  • Known history of arrhythmia or uncontrolled arrhythmia
  • Known history of clinically significant drug allergy at Screening
  • Known history of food allergies or presently experiencing significant seasonal or perennial allergy at Screening
  • Known to be (HIV) positive at Screening
  • Active viral hepatitis (A, B, or C) as demonstrated by positive serology at Screening
  • History of drug or alcohol dependency or abuse within the 2 years prior to Screening, or those who have a positive urine drug and alcohol test at Screening or Baseline
  • Intake of herbal preparations containing St. John's Wort within 4 weeks before dosing
  • Use of prescription drugs within 4 weeks before dosing
  • Intake of over-the-counter (OTC) medications within 2 weeks before dosing
  • Currently enrolled in another clinical study or used any drug or device within 30 days (or 5 half-lives, whichever is longer) before
  • Receipt of blood products within 4 weeks, or donation of blood within 8 weeks, or donation of plasma within 1 week before dosing
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Cohort 1: 10 mg E6742

    Participants will receive 10 milligrams (mg) E6742 as a single oral dose in the fasted state.

    Drug: E6742

  • Placebo comparator
    Cohort 1: Matching placebo

    Participants will receive a single oral dose of placebo matching E6742 in the fasted state.

    Drug: Placebo

  • Experimental
    Cohort 2: 25 mg E6742

    Participants will receive 25 mg E6742 as a single oral dose in the fasted state.

    Drug: E6742

  • Placebo comparator
    Cohort 2: Matching placebo

    Participants will receive a single oral dose of placebo matching E6742 in the fasted state.

    Drug: Placebo

  • Experimental
    Cohort 3: 50 mg E6742

    Participants will receive 50 mg E6742 as a single oral dose in the fasted state.

    Drug: E6742

  • Placebo comparator
    Cohort 3: Matching placebo

    Participants will receive a single oral dose of placebo matching E6742 in the fasted state.

    Drug: Placebo

  • Experimental
    Cohort 4: 100 mg E6742

    Participants will receive 100 mg E6742 as a single oral dose in the fasted state. Participants will then receive the same single oral dose of E6742 again in the fed state after a washout interval (at least 7 days or 5 half-lives of E6742, whichever is longer) for the evaluation of food effect.

    Drug: E6742

  • Placebo comparator
    Cohort 4: Matching placebo

    Participants will receive a single oral dose of placebo matching E6742 in the fasted state. Participants will then receive the same single oral dose of placebo again in the fed state after a washout interval (at least 7 days ) for the evaluation of food effect.

    Drug: Placebo

  • Experimental
    Cohort 5: 200 mg E6742

    Participants will receive 200 mg E6742 as a single oral dose in the fasted state.

    Drug: E6742

  • Placebo comparator
    Cohort 5: Matching placebo

    Participants will receive a single oral dose of placebo matching E6742 in the fasted state.

    Drug: Placebo

  • Experimental
    Cohort 6: 400 mg E6742

    Participants will receive 400 mg E6742 as a single oral dose in the fasted state.

    Drug: E6742

  • Placebo comparator
    Cohort 6: Matching placebo

    Participants will receive a single oral dose of placebo matching E6742 in the fasted state.

    Drug: Placebo

  • Experimental
    Cohort 7: 800 mg E6742

    Participants will receive 800 mg E6742 as a single oral dose in the fasted state.

    Drug: E6742

  • Placebo comparator
    Cohort 7: Matching placebo

    Participants will receive a single oral dose of placebo matching E6742 in the fasted state.

    Drug: Placebo

Interventions

  • DrugE6742

    gelatin capsules

  • DrugPlacebo

    gelatin capsules

06

What researchers measure

Primary outcomes

  1. Number of participants with any serious adverse event and number of participants with any non-serious adverse event

    The number of participants with any serious adverse event and the number of participants with any non-serious adverse event will be reported.

    Time frame: from Screening up to Day 7

  2. Mean maximum observed concentration (Cmax) of E6742 and the metabolite ER-1132963 in plasma

    Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 \[7 days\] and 2 \[6 days\]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).

    Time frame: Days 1 to 7

  3. Time at which the highest drug concentration occurs (tmax) for E6742 and the metabolite ER-1132963 in plasma

    Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 \[7 days\] and 2 \[6 days\]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).

    Time frame: Days 1 to 7

  4. Area under the concentration-time curve from zero time to 24 hours postdose (AUC[0-24h]) E6742 and the metabolite ER-1132963 in plasma

    Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 \[7 days\] and 2 \[6 days\]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).

    Time frame: Days 1 to 7

  5. Area under the concentration-time curve from zero time to 72 hours postdose (AUC[0-72h]) for E6742 and the metabolite ER-1132963 in plasma

    Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 \[7 days\] and 2 \[6 days\]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).

    Time frame: Days 1 to 7

  6. Area under the concentration-time curve from zero time to time of last quantifiable concentration (AUC[0-t]) for E6742 and the metabolite ER-1132963 in plasma

    Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 \[7 days\] and 2 \[6 days\]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).

    Time frame: Days 1 to 7

  7. Area under the concentration-time curve from zero time extrapolated to infinite time (AUC[0-inf]) for E6742 and the metabolite ER-1132963 in plasma

    Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 \[7 days\] and 2 \[6 days\]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).

    Time frame: Days 1 to 7

  8. Terminal elimination phase half-life (t1/2) for E6742 and the metabolite ER-1132963 in plasma

    Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 \[7 days\] and 2 \[6 days\]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).

    Time frame: Days 1 to 7

  9. Apparent total clearance following extravascular administration (CL/F) for E6742 in plasma

    Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 \[7 days\] and 2 \[6 days\]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).

    Time frame: Days 1 to 7

  10. Apparent volume of distribution at terminal phase (Vz/F) for E6742 in plasma

    Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 \[7 days\] and 2 \[6 days\]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).

    Time frame: Days 1 to 7

  11. AUC metabolite to E6742 ratio following molecular weight correction to E6742 equivalents in plasma

    Cohorts 1, 2, 3, 5, and 6: Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose). Cohort 4: In both periods (Treatment Periods 1 \[7 days\] and 2 \[6 days\]), Day 1 at predose and 0.5 (30 minutes), 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose; Day 2 (24 and 36 hours postdose); Day 3 (48 hours postdose); Day 4 (72 hours postdose); Day 5 (96 hours postdose); Day 6 (120 hours postdose); Day 7 (144 hours postdose).

    Time frame: Days 1 to 7

  12. Amount of unchanged drug excreted in urine (Ae) for E6742 and the metabolite ER-1132963

    Cohorts 1, 2, 3, 5, and 6: Days 1 to 7: predose and 0 to 4, \>4 to 8, \>8 to 12, \>12 to 24, \>24 to 48, \>48 to 72, \>72 to 96, \>96 to 120, and \>120 to 144 hours postdose. Cohort 4: Days 1 to 7 (Treatment Period 1): predose and 0 to 4, \>4 to 8, \>8 to 12, \>12 to 24, \>24 to 48, \>48 to 72, \>72 to 96, \>96 to 120, and \>120 to 144 hours postdose.

    Time frame: Days 1 to 7

  13. Renal clearance (CLR)

    Cohorts 1, 2, 3, 5, and 6: Days 1 to 7: predose and 0 to 4, \>4 to 8, \>8 to 12, \>12 to 24, \>24 to 48, \>48 to 72, \>72 to 96, \>96 to 120, and \>120 to 144 hours postdose. Cohort 4: Days 1 to 7 (Treatment Period 1): predose and 0 to 4, \>4 to 8, \>8 to 12, \>12 to 24, \>24 to 48, \>48 to 72, \>72 to 96, \>96 to 120, and \>120 to 144 hours postdose.

    Time frame: Days 1 to 7

07

Study locations

1 site
  • Parexel International
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Oct 2017, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2017
First posted
Mar 17, 2017
StartActual
Mar 3, 2017
Primary completionActual
Oct 11, 2017
CompletionActual
Oct 11, 2017
Last update
Sep 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03082235
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Mar 17, 2017
Start date
Mar 3, 2017
Primary completion
Oct 11, 2017
Completion
Oct 11, 2017
Last update
Sep 7, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: E6742

Start the discussion